Inhibition of RAGE Axis Signaling: A Pharmacological Challenge

Curr Drug Targets. 2019;20(3):340-346. doi: 10.2174/1389450119666180820105956.

Abstract

The Receptor for Advanced Glycation End Products (RAGE) is an important cell surface receptor, which belongs to the IgG super family and is now considered as a pattern recognition receptor. Because of its relevance in many human clinical settings, it is now pursued as a very attractive therapeutic target. However, particular features of this receptor such as a wide repertoire of ligands with different binding domains, the existence of many RAGE variants as well as the presence of cytoplasmatic adaptors leading a diverse signaling, are important limitations in the search for successful pharmacological approaches to inhibit RAGE signaling. Therefore, the present review aimed to display the most promising approaches to inhibit RAGE signaling, and provide an up to date review of progress in this area.

Keywords: Receptor of advanced glycation end-products; advanced glycation end-products; antagonists; cytoplasmatic adaptors; inhibitors; intracellular signaling..

Publication types

  • Review

MeSH terms

  • Animals
  • Biological Products / pharmacology
  • Drug Development
  • Glycation End Products, Advanced / metabolism
  • Humans
  • Ligands
  • Receptor for Advanced Glycation End Products / antagonists & inhibitors
  • Receptor for Advanced Glycation End Products / metabolism*
  • Signal Transduction / drug effects*
  • Small Molecule Libraries / pharmacology

Substances

  • Biological Products
  • Glycation End Products, Advanced
  • Ligands
  • Receptor for Advanced Glycation End Products
  • Small Molecule Libraries